Literature DB >> 12531510

Insoluble TATA-binding protein accumulation in Huntington's disease cortex.

Willeke M C van Roon-Mom1, Suzanne J Reid, A Lesley Jones, Marcy E MacDonald, Richard L M Faull, Russell G Snell.   

Abstract

Huntington's disease is a dominantly inherited neurological disorder where specific neurodegeneration is caused by an extended polyglutamine stretch in the huntingtin protein. Proteins with expanded polyglutamine regions have the ability to self-aggregate and previous work in our laboratory, and by others, revealed sparse amyloid-like deposits in the Huntington's disease brain, supporting the hypothesis that the polyglutamine stretches may fold into regular beta-sheet structures. This process of folding has similarities to other neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and the prion diseases which all exhibit beta-sheet protein accumulation. We were therefore interested in testing the hypothesis that TATA-binding protein may play a role in Huntington's disease as it contains an elongated polymorphic polyglutamine stretch that ranges in size from 26 to 42 amino acids in normal individuals. A proportion of TBP alleles fall within the range of glutamine length that causes neurodegeneration when located in the huntingtin protein. In this study the distribution and cellular localisation of TATA-binding protein was compared to the distribution and cellular localisation of the huntingtin protein in the middle frontal gyrus of Huntington's disease and neurologically normal subjects. Seven different morphological forms of TATA-binding protein-positive structures were detected in Huntington's disease but not in control brain. TATA-binding protein labelling was relatively more abundant than huntingtin labelling and increased with the grade of the disease. At least a proportion of this accumulated TBP exists as insoluble protein. This suggests that TBP may play a role in the disease process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12531510     DOI: 10.1016/s0169-328x(02)00450-3

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  20 in total

1.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

2.  Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction.

Authors:  Tomoyuki Yamanaka; Asako Tosaki; Haruko Miyazaki; Masaru Kurosawa; Yoshiaki Furukawa; Mizuki Yamada; Nobuyuki Nukina
Journal:  Hum Mol Genet       Date:  2010-02-25       Impact factor: 6.150

3.  Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones.

Authors:  Huanhuan Luo; Liying Cao; Xuan Liang; Ana Du; Ting Peng; He Li
Journal:  Mol Neurobiol       Date:  2018-02-12       Impact factor: 5.590

4.  A Drosophila model of the neurodegenerative disease SCA17 reveals a role of RBP-J/Su(H) in modulating the pathological outcome.

Authors:  Jie Ren; Anil G Jegga; Minlu Zhang; Jingyuan Deng; Junbo Liu; Christopher B Gordon; Bruce J Aronow; Long J Lu; Bo Zhang; Jun Ma
Journal:  Hum Mol Genet       Date:  2011-06-08       Impact factor: 6.150

Review 5.  Genetics and neuropathology of Huntington's disease.

Authors:  Anton Reiner; Ioannis Dragatsis; Paula Dietrich
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

6.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

7.  Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor.

Authors:  Tomoyuki Yamanaka; Haruko Miyazaki; Fumitaka Oyama; Masaru Kurosawa; Chika Washizu; Hiroshi Doi; Nobuyuki Nukina
Journal:  EMBO J       Date:  2008-02-21       Impact factor: 11.598

Review 8.  Spinocerebellar ataxia type 17 is caused by mutations in the TATA-box binding protein.

Authors:  Christine Zühlke; Katrin Bürk
Journal:  Cerebellum       Date:  2007-01-19       Impact factor: 3.847

9.  Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains.

Authors:  Emily S Herndon; Christa L Hladik; Ping Shang; Dennis K Burns; Jack Raisanen; Charles L White
Journal:  J Neuropathol Exp Neurol       Date:  2009-03       Impact factor: 3.685

10.  Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4).

Authors:  Giovanni Stevanin; Alexis Brice
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.